샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795831

세계의 저분자 CDMO 시장

Small Molecules Contract Development and Manufacturing Organization
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 479 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

저분자 CDMO 세계 시장은 2030년까지 2,406억 달러에 달할 전망

2024년에 1,751억 달러로 추정되는 저분자 CDMO 세계 시장은 분석 기간인 2024-2030년에 CAGR 5.4%로 성장하여 2030년에는 2,406억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 저분자 원료의약품은 CAGR 4.4%를 기록하며 분석 기간 종료시에는 1,503억 달러에 달할 것으로 예측됩니다. 저분자 의약품 부문의 성장률은 분석 기간 동안 CAGR 7.3%로 추정됩니다.

미국 시장은 477억 달러로 추정, 중국은 CAGR 8.4%로 성장 예측

미국의 저분자 CDMO 시장은 2024년에 477억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 478억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.7%와 5.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 3.5%로 성장할 것으로 예측됩니다.

세계의 저분자 CDMO 시장 - 주요 동향과 촉진요인 정리

저분자 CDMO가 세계 의약품 공급망에서 중요한 축이 된 이유는 무엇일까?

저분자 의약품 개발 제조 수탁기관(CDMO)은 의약품 가치사슬에 필수적인 존재로, 원료의약품(API) 및 제제(제형) 개발을 위한 엔드투엔드 서비스를 제공하고 있습니다. 제약사들이 업무를 간소화하고, 시장 출시 시간을 단축하고, 비용과 생산능력에 대한 압박에 대응하기 위해 복잡한 저분자 프로젝트를 전문 CDMO에 위탁하는 사례가 증가하고 있습니다. 이러한 파트너는 전임상 단계의 연구개발에서 상업적 생산으로 확장하는 데 매우 중요한 요소인 공정 화학에 대한 깊은 전문 지식, 세계 규제에 대한 이해, 첨단 인프라를 제공합니다.

저분자는 특히 종양학, 심장병학, 중추신경계 질환, 감염질환 등의 영역에서 현재도 시판되고 있는 의약품의 대부분을 차지하고 있습니다. 비교적 안정적인 제제, 확립된 규제 경로, 경구 생체 이용률로 인해 생물학적 제제 붐 속에서도 저분자는 지배적인 치료 수단으로 자리 잡았습니다. 그 결과, 저분자 의약품의 강력한 역량을 갖춘 CDMO는 대형 제약사뿐만 아니라 의약품 후보물질을 출시하기 위해 확장 가능하고 GMP에 부합하는 인프라를 필요로 하는 중견기업 및 바이오벤처 기업들에게도 여전히 높은 인기를 누리고 있습니다.

기술과 규제의 복잡성은 CDMO의 서비스 모델을 어떻게 형성하고 있는가?

최신 CDMO가 제공하는 서비스의 범위는 기본적인 위탁 제조에서 포괄적이고 통합적인 제공으로 진화하고 있습니다. 여기에는 공정 개발, 분석법 검증, 고체 화학, 규제 당국 신청 지원, 제형 설계, 포장 솔루션 등이 포함됩니다. 첨단 CDMO는 사이클 타임, 환경 발자국, 배치당 비용을 줄이기 위해 연속 제조, 친환경 화학, 자동화 기술에 투자하고 있습니다.

동시에 규제 환경도 복잡해지고 있습니다. FDA, EMA, PMDA와 같은 기관은 더 깊은 프로세스 투명성, 데이터 무결성, QbD(Quality-by-Design) 접근법을 요구하고 있습니다. CDMO는 강력한 디지털 문서화 시스템, 실시간 배치 분석, 시설 전체의 엄격한 품질 시스템을 통해 이러한 기대에 부응해야 합니다. 세계 규제 조화가 진행됨에 따라 다국적 기업 고객들은 국경을 초월한 컴플라이언스 전문성과 여러 시설의 규제 인증을 보유한 CDMO를 요구하고 있으며, 이는 고성능 벤더 간의 통합 추세에 박차를 가하고 있습니다.

저분자 CDMO에 대한 수요가 가장 급증하는 곳은 어디인가?

저분자 CDMO에 대한 수요가 가장 급증하고 있는 분야는 신흥 바이오제약 분야로, 현재 전 세계 초기 단계의 의약품 개발 활동의 대부분을 차지하고 있습니다. 이들 기업은 자체 생산능력이 없기 때문에 위탁생산에 크게 의존하고 있습니다. 암 분야와 희귀질환 분야는 대부분 저분자를 주성분으로 하고 있으며, 특히 1상 및 2상 임상시험에서 큰 프로젝트 물량에 기여하고 있습니다. 블록버스터 의약품의 특허 절벽이 다가옴에 따라 대형 제약사들은 제네릭 의약품과 복합제, 합제를 포함한 라이프사이클 연장 업무도 아웃소싱하고 있습니다.

지역별로는 북미가 여전히 가장 큰 시장이며, 엄격한 규제와 높은 품질 기준으로 인해 프리미엄 CDMO 파트너에 대한 수요가 증가하고 있는 유럽이 근소한 차이로 그 뒤를 잇고 있습니다. 그러나 아시아태평양은 특히 인도와 중국에서 경쟁력 있는 비용 구조, GMP 준수 확대, 인력 풀 증가를 배경으로 중요한 제조 거점으로 부상하고 있습니다. 또한, 미국과 유럽에서는 온쇼어링이 눈에 띄게 증가하고 있으며, CDMO는 지정학적 리스크를 줄이고 공급망 연속성을 보장하기 위해 현지 생산능력을 확대해야 할 필요성이 대두되고 있습니다.

저분자 CDMO 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다...

의약품 개발 라이프사이클 전반에 걸쳐 확장 가능한 고품질 아웃소싱 솔루션에 대한 수요가 지속적으로 증가함에 따라 시장이 확대되고 있습니다. 특히 만성질환 및 신흥질환을 대상으로 하는 저분자 의약품이 세계 파이프라인에서 우위를 점하고 있으며, 지속적인 수요가 확실시되고 있습니다. 신생 바이오제약사들의 R&D 투자 증가는 한정된 자체 생산 자원과 함께 CDMO 의존도를 더욱 높이고 있습니다. 연속 제조, 고역가 화합물 취급, 디지털 공정 분석의 기술 발전은 CDMO의 가치 제안을 향상시키고 있습니다. 또한, 규제 복잡성, GMP 준수에 대한 압박, 공급망의 세계화로 인해 제약사들은 장기적이고 전략적인 아웃소싱 파트너십을 체결하고 있습니다. 아시아태평양의 성장은 주요 CDMO의 생산능력 확대 및 M&A 활동과 함께 임상 및 상업적 단계에서 시장의 모멘텀을 더욱 가속화하고 있습니다.

부문

제품 유형(저분자 원료의약품, 저분자 의약품), 스테이지(전임상 스테이지, 임상 스테이지, 상업 스테이지), 치료 분야(암 치료 영역, 심혈관질환 치료 분야, 호흡기질환 치료 분야, 신경 치료 분야, 대사질환 치료 분야, 기타 치료 분야), 최종사용자(제약·바이오테크놀러지 기업 최종사용자, 연구기관·아카데믹 최종사용자)

조사 대상 기업 사례

  • Ajinomoto Bio-Pharma Services
  • Aenova Group
  • Alcami Corporation
  • Amgen Inc.
  • Aurigene Pharmaceutical Services Ltd.
  • Bellen Chemistry
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Eurofins Scientific
  • Hovione
  • Labcorp Drug Development
  • Lonza Group Ltd.
  • Pace Analytical Services, LLC
  • Piramal Pharma Solutions
  • WuXi AppTec Co., Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.01

Global Small Molecules Contract Development and Manufacturing Organization Market to Reach US$240.6 Billion by 2030

The global market for Small Molecules Contract Development and Manufacturing Organization estimated at US$175.1 Billion in the year 2024, is expected to reach US$240.6 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Small Molecule API, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$150.3 Billion by the end of the analysis period. Growth in the Small Molecule Drug Products segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$47.7 Billion While China is Forecast to Grow at 8.4% CAGR

The Small Molecules Contract Development and Manufacturing Organization market in the U.S. is estimated at US$47.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$47.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Small Molecules CDMO Market - Key Trends & Drivers Summarized

Why Are Small Molecule CDMOs Now Critical Pillars in Global Pharma Supply Chains?

Small Molecule Contract Development and Manufacturing Organizations (CDMOs) have become integral to the pharmaceutical value chain, offering end-to-end services for drug substance (API) and drug product (formulation) development. As pharmaceutical companies streamline operations, reduce time-to-market, and respond to cost and capacity pressures, they are increasingly outsourcing complex small molecule projects to specialized CDMOs. These partners bring deep process chemistry expertise, global regulatory understanding, and advanced infrastructure-factors crucial for scaling from preclinical R&D to commercial manufacturing.

Small molecules still account for the vast majority of drugs on the market, particularly in areas like oncology, cardiology, CNS disorders, and infectious diseases. Their relatively stable formulations, well-established regulatory pathways, and oral bioavailability make them the dominant therapeutic modality even amid the biologics boom. Consequently, CDMOs with robust small molecule capabilities remain highly sought after-not only by large pharmaceutical companies but also by mid-sized firms and biotech startups needing scalable, GMP-compliant infrastructure to bring drug candidates to market.

How Are Technology and Regulatory Complexity Shaping CDMO Service Models?

The scope of services provided by modern CDMOs has evolved from basic contract manufacturing to comprehensive, integrated offerings. These include process development, analytical method validation, solid-state chemistry, regulatory submission support, formulation design, and packaging solutions. Advanced CDMOs are investing in continuous manufacturing, green chemistry, and automation technologies to reduce cycle times, environmental footprint, and cost per batch-an advantage especially for high-volume or niche indication drugs.

Simultaneously, the regulatory environment is growing more intricate. Agencies like the FDA, EMA, and PMDA are requiring deeper process transparency, data integrity, and quality-by-design (QbD) approaches. CDMOs must meet these expectations through robust digital documentation systems, real-time batch analytics, and stringent quality systems across facilities. As global regulatory harmonization gains traction, multinational clients are seeking CDMOs with cross-border compliance expertise and multi-site regulatory accreditations-spurring a consolidation trend among high-performing vendors.

Where Is Demand for Small Molecule CDMOs Surging the Most?

The fastest-growing demand for small molecule CDMOs is coming from emerging biopharma, which now accounts for the majority of early-stage drug development activity worldwide. These companies rely heavily on outsourced manufacturing due to lack of in-house capabilities. Oncology and rare disease segments-many of which are dominated by small molecules-are contributing significant project volume, especially for Phase I and II clinical trials. As patent cliffs approach for blockbuster drugs, large pharma companies are also outsourcing generics and lifecycle extension work, including reformulations and fixed-dose combinations.

Regionally, North America remains the largest market, followed closely by Europe, where regulatory stringency and high-quality standards elevate demand for premium CDMO partners. However, Asia-Pacific is emerging as a key manufacturing hub, particularly in India and China, driven by competitive cost structures, expanding GMP compliance, and growing talent pools. There is also a notable rise in onshoring initiatives in the US and Europe, prompting CDMOs to expand local capacity to mitigate geopolitical risks and ensure supply chain continuity.

The Growth in the Small Molecules CDMO Market Is Driven by Several Factors…

The market is expanding due to sustained demand for scalable, high-quality outsourcing solutions across the drug development lifecycle. The dominance of small molecule drugs in global pipelines, particularly for chronic and emerging diseases, ensures strong underlying demand. Rising R&D investments by emerging biopharma, coupled with limited internal manufacturing resources, are fueling CDMO dependency. Technological advancements in continuous manufacturing, high-potency compound handling, and digital process analytics are increasing the value proposition of CDMOs. Additionally, rising regulatory complexity, GMP compliance pressures, and supply chain globalization are prompting pharmaceutical companies to form long-term, strategic outsourcing partnerships. Regional growth in Asia-Pacific, combined with capacity expansions and M&A activity among leading CDMOs, is further amplifying market momentum across clinical and commercial phases.

SCOPE OF STUDY:

The report analyzes the Small Molecules Contract Development and Manufacturing Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Small Molecule API, Small Molecule Drug Products); Stage (Preclinical Stage, Clinical Stage, Commercial Stage); Therapeutic Area (Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area, Neurology Therapeutic Area, Metabolic Disorders Therapeutic Area, Other Therapeutic Areas); End-Use (Pharma & Biotech Companies End-Use, Research Institutes & Academics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Ajinomoto Bio-Pharma Services
  • Aenova Group
  • Alcami Corporation
  • Amgen Inc.
  • Aurigene Pharmaceutical Services Ltd.
  • Bellen Chemistry
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Eurofins Scientific
  • Hovione
  • Labcorp Drug Development
  • Lonza Group Ltd.
  • Pace Analytical Services, LLC
  • Piramal Pharma Solutions
  • WuXi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Small Molecules Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Resurgence of Small Molecule Drug Pipelines Propels Growth of CDMO Partnerships
    • Rising Complexity of API Synthesis Strengthens Business Case for Outsourced Small Molecule Manufacturing
    • Increased Demand for Accelerated Clinical Development Timelines Spurs CDMO Adoption
    • Expansion of Oncology and CNS Drug Development Pipelines Generates Demand for Specialized CDMO Capabilities
    • Outsourcing by Emerging Biopharma Expands Addressable Market for CDMOs Focused on Small Molecules
    • Regulatory Pressure to Ensure GMP Compliance Drives Demand for Experienced CDMO Partners
    • High Cost of In-House Manufacturing Infrastructure Boosts Reliance on End-to-End CDMO Solutions
    • Trend Toward Continuous Manufacturing in Small Molecules Creates Opportunities for Process-Capable CDMOs
    • Shift Toward Niche and Orphan Drug Development Spurs Need for Flexible, Small-Scale CDMO Operations
    • Growing Adoption of Green Chemistry in Pharma Manufacturing Drives Innovation Across CDMOs
    • Rapid Globalization of Clinical Trials Expands Demand for CDMOs with Multiregional Regulatory Expertise
    • Supply Chain Disruptions and Risk Mitigation Strategies Accelerate Dual Sourcing Through CDMOs
    • Digitalization and Data Analytics in Drug Development Strengthen Competitive Edge for Smart CDMOs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Small Molecules Contract Development and Manufacturing Organization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecule API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecule Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Small Molecule Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Small Molecule Drug Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Metabolic Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cardiovascular Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Respiratory Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutes & Academics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Research Institutes & Academics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Research Institutes & Academics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Preclinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Preclinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Preclinical Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Clinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Clinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Clinical Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Commercial Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Commercial Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Commercial Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • JAPAN
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • CHINA
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • EUROPE
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • FRANCE
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • GERMANY
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • INDIA
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
  • AFRICA
    • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제